CPDC and McMaster Nuclear Reactor Sign Research Agreement for Production of High Value Medical Isotopes
The Centre for Probe Development and Commercialization (CPDC), a global leader in the development, production and commercialization of radiopharmaceuticals, and the McMaster Nuclear Reactor facility (MNR), a leading research reactor program that provides a source of medical radioisotopes, announced today that they have signed an agreement to explore the development of processes to produce rare and high-value medical radioisotopes utilizing the nuclear reactor at McMaster University in Hamilton, Ontario and CPDC’s GMP production capabilities. The companies have signed a Memorandum of Understanding to explore the production and processing of important radioisotopes that are increasing in clinical utility but are in limited supply.
“The combination of expertise that has been built at MNR and CPDC and leveraged at McMaster is another great example of our ability to capitalize on our unique strengths to develop research partnerships,” said Karen Mossman, acting Vice President, Research. “This joint-development project has great potential to address a growing concern in nuclear medicine and will accelerate the commercialization of our world-class research.”
“MNR is a world leader in the production of critical radioisotopes, including iodine-125 used in the treatment of cancer,” commented Chris Heysel, McMaster University’s Director of Nuclear Operations and Facilities. “By developing innovative production methods the CPDC-MNR plan will ensure that the medical community has access to a reliable source of medical radioisotopes for both therapeutic and diagnostic purposes.”
Dr. Robert Sutherland, Chair of CPDC, remarked that “CPDC was recently awarded $10.5 million in federal funding, earmarked in part to help reinforce the role of Canada as a global leader in the development and supply of medical isotopes.” The funding announcement also acknowledged CPDC as the only National Centre of Excellence for Commercialization and Research to receive three consecutive rounds of federal NCE funding.
Dr. Joe McCann, CPDC’s Chief Operating Officer, described the agreement as timely since the need for high quality medical isotopes is growing dramatically as new innovative therapies are entering clinical trials and nearing market authorization. “There currently exists a significant gap in the supply of certain high quality, GMP-grade medical radioisotopes in North America to ensure patient access to the new therapies coming to market. This agreement presents a unique opportunity to combine the strengths of MNR in radioisotope R&D and production with CPDC’s strengths in quality, regulatory, GMP and commercialization to create solutions that will address an unmet need in medical isotope supply. This collaboration has tremendous potential to make a significant impact on patient care in Canada and globally.” CPDC is involved in a number of late clinical stage radiopharmaceutical development programs that will benefit directly through this enhanced relationship with MNR.
Radioisotopes and radiopharmaceuticals are increasingly being used to treat deadly diseases like neuroendocrine tumours and prostate cancer. CPDC’s contract manufacturing division is supplying radiopharmaceutical drugs for each of these disease indications yet the true potential for improvement in patient care is constrained by the lack of availability of certain radioisotopes. The joint CPDC-MNR effort will explore how specific isotopes can be produced in MNR’s reactor. Reactor operations, isotope production and processing will be completed by MNR while the final GMP radioisotope product will be produced by CPDC. The objective of the joint-effort is to meet the growing demand for these isotopes.
Centre for Probe Development and Commercialization (CPDC) is a Centre of Excellence for Commercialization and Research (CECR) located at McMaster University in Hamilton, Ontario, Canada. CPDC is a private, not-for-profit company and global leader in the discovery, development and commercialization of next generation radiopharmaceuticals that was created with the support of multiple stakeholders, including the Networks of Centres of Excellence (NCE) and the Ontario Institute for Cancer Research (OICR). Since its foundation in 2008, CPDC has established a robust and reliable global supply of innovative diagnostic and therapeutic radiopharmaceuticals used daily for the detection and treatment of human diseases such as cancer. For more information about CPDC, please visit: www.imagingprobes.ca.
About McMaster Nuclear Reactor
McMaster University is Canada’s preeminent nuclear research institution and houses an integrated suite of research facilities that enable discoveries in medicine, clean energy, nuclear safety, materials and environmental science. The central facility within Nuclear Operations is the McMaster Nuclear Reactor (MNR) – a multi-purpose reactor that provides neutrons for medical isotope production and research. Learn more at mnr.mcmaster.ca.
Centre for Probe Development and Commercialization
Michael Cross, 905 525-9140, ext. 21212
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Ipsen Receives Positive CHMP Opinion for Cabometyx® (Cabozantinib) for the Second-line Treatment of Patients with Hepatocellular Carcinoma (HCC)21.9.2018 05:30 | Pressemelding
Regulatory News: Ipsen (Euronext:IPN; ADR:IPSEY) announced today that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), provided a positive opinion for Cabometyx® (cabozantinib) as a monotherapy for the treatment of hepatocellular carcinoma (HCC) in adults who have been previously treated with sorafenib. The CHMP positive opinion will now be reviewed by the European Commission (EC), which has the authority to approve medicines for the European Union (EU). Alexandre Lebeaut, MD, Executive Vice President, R&D and Chief Scientific Officer, Ipsen, said: “The global burden of liver cancer is increasing and despite the recent introduction of new agents, it remains the second leading cause of cancer mortality worldwide. Following today’s positive CHMP opinion and if approved by the European Commission, Cabometyx ® as monotherapy will give patients with HCC a much-needed new oral therapeutic option.” Dr Lorenza Rimassa,
Quanergy Selected as Exclusive LiDAR Partner for VRCO21.9.2018 05:00 | Pressemelding
Quanergy Systems, Inc., a global leader in the design and development of solid state LiDAR sensors and smart sensing solutions, and VRCO, designer and manufacturer of the luxury high-end e-VTOL (electric Vertical Take-Off and Landing) craft, the NeoXcraft XP2, today announced that VRCO will exclusively use Quanergy’s S3 solid state LiDAR sensors in the testing and market release versions of the aircraft. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180920006036/en/ VRCO NeoXcraft XP2 with Quanergy S3 LiDAR Sensor (Graphic: Business Wire) The NeoXcraft XP2, which VRCO and the University of Derby unveiled in late 2017 and intend to launch in 2020, is a two-passenger e-VTOL high-speed land, air, and water capable craft. The craft can scan and memorize take-off locations and store the data for use on the next approach to the same location. Quanergy’s innovative S3 solid state LiDAR sensor will be used for downward and forward
Overseas Roadshow for the IAPH Guangzhou 2019 World Ports Conference Was Held in London21.9.2018 03:08 | Pressemelding
Overseas roadshow for the IAPH Guangzhou 2019 World Ports Conference was successfully held in Armourer's Hall, London, UK on September 20th. Ms. Yuan Yue, Deputy Director General of Guangzhou Port Authority, met with over 100 senior representatives from British ports, ship-owners, commodity traders, shipping & service companies, shipping public policy research institutes, and other representatives from the port and shipping industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180920006031/en/ Speech made by Lord Jeffrey Evans, Chairman of Maritime London (Photo: Business Wire) In her keynote speech, Ms. Yuan Yue said, “Guangzhou is the gateway city of South China and is known as the “Millennium Business Capital” and a popular destination for business and investment. At present, Guangzhou has attracted investors from over 130 countries. Nearly 300 of the world's top 500 companies have businesses and investment in Guangzho
AbuDhabi Dubai STOB Series 22 Investment Enters into Favorable Tender Offer Agreement with MINDOL HOLDINGS21.9.2018 01:00 | Pressemelding
AbuDhabi Dubai STOB Series 22 Investment Limited Partnership, hereafter AbuDhabi22, and MINDOL HOLDINGS LIMITED, hereafter MINDOL, listed on the Hong Kong-based Coinsuper exchange (https://www.coinsuper.com) have reached an agreement where AbuDhabi22 will acquire the minimum 33.3 percent holding for the MINDOL cryptocurrency (MIN, https://mindol.net) to be issued by MINDOL, via a tender offer (TOB). Implementation of the TOB will serve to strengthen the strategic partnership with MINDOL. Both companies expect that the AbuDhabi22 bid will greatly exceed any bids made via ordinary exchange channels. With a bid offering at a stable price, the TOB method was chosen for its strategic worth. The MINDOL business vision for 2019 sets a target for its cryptocurrency, from among the more than 2,000 types of cryptocurrencies currently available, to have a top-30 market capitalization. As a business that focuses on "the fusion of subculture and blockchain," they will develop an online game that ta
Afton Chemical’s S$380 Million Phase II Expansion of Its Jurong Island Plant is Now Complete20.9.2018 21:07 | Pressemelding
Afton Chemical Corporation, a global leader in the lubricant and fuel additive market, today announced the completion of the Phase II expansion of its Chemical Additive Manufacturing Facility in Jurong Island, Singapore. This milestone was marked by a special visit from Singapore’s Minister for Trade & Industry Mr. Chan Chun Sing, who also made a speech and toured the facility. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180920005903/en/ Afton Chemical Corporation – Singapore Chemical Additive Manufacturing Facility Phase II Expansion (Photo: Business Wire) As a wholly owned subsidiary of NewMarket Corporation (NYSE: NEU), Afton has been a leading player in the lubricant and fuel additive marketplace for over 90 years. The company was founded on a Passion for Solutions® and has maintained a focus on customizing commercial and industrial solutions that meet customer needs. Afton begun its Singapore manufacturing operations
IFF Announces Pricing of €1,100,000,000 Senior Notes Offering20.9.2018 20:15 | Pressemelding
Regulatory News: International Flavors & Fragrances Inc. (NYSE:IFF) (Euronext Paris: IFF), a leading innovator of sensorial experiences that move the world, today announced that it has priced its public offering of €300,000,000 aggregate principal amount of its 0.500% senior notes due 2021 and €800,000,000 aggregate principal amount of its 1.800% senior notes due 2026. IFF intends to use the net proceeds from the offering to pay a portion of the consideration for the previously announced merger with Frutarom Industries Ltd. and to pay related fees and expenses. IFF anticipates that the offering will close on September 25, 2018, subject to customary closing conditions. The offering is not contingent upon the consummation of the merger. If the closing of the merger has not occurred on or prior to February 7, 2019, or, if prior to such date, the merger agreement with Frutarom is terminated, IFF will be required to redeem all of the notes on the special mandatory redemption date at a redem